


| Title  | Warfarin Reversal Chart                          |
|--|--|
| Document Type  | Clinical Guideline                               |
| Version number   | PX122/3  |
| Approval/Issue date  | March 2016/Update April 2021/Update October 2021 |
| Review date  | April 2023                                       |
| Approved by  | NHS Borders Clinical Staff                       |
| Owner/Person<br>Responsible                                    | Liz Leitch, Formulary Pharmacist                 |
| Developed by   | Dr Rosie Jones; Liz Leitch                       |
| Reviewed by  | NHS Borders Anticoagulation Committee            |
| Healthcare Inequality Impact Assessed (statutory for policies) | N/A  |

**Uncontrolled when printed** 

# NHS BORDERS GUIDE TO REVERSAL OF ORAL ANTICOAGULATION ON WARFARIN CLASSIFICATION OF BLEEDING COMPLICATIONS





## **Classification of Haemorrhage**

### **Fatal**

Death due to haemorrhage (Demonstrated at autopsy, radiologically or clinically obvious)

## Major **Y**

Intracranial (CT or MRI documented)

Retroperitoneal (CT or MRI documented)

Intra-ocular (excludes conjunctival) Spontaneous

muscle haematoma associated with compartment syndrome Pericardial

Non-traumatic intra-articular

Any invasive procedure to stop bleeding Active bleeding

from any orifice plus
BP≤90mmHg systolic,or oliguria or
≥20g/l fall in haemoglobin

#### Minor

Any other bleeding that would not influence your decision to anticoagulate a patient

Adapted from NHS Lothian guidance March 2016. Updated October 2021. Review Date April 2023

#### Cautions

♦Beriplex P/N contains heparin and is contraindicated in patients with heparin induced thrombocytopenia (present or previous)

Beriplex P/N is also relatively contraindicated in patients with:

- 1. An increased risk of thrombosis
- 2. Angina pectoris and after recent myocardial infarction

In all clinical situations an assessment of the likely risks and benefits of administration needs to be made.

In disseminated intravascular coagulation, prothrombin complex-preparations (e.g. Beriplex P/N) may only be administered after termination of the consumptive state.

- † Intravenous vitamin K (phytomenadione) may rarely cause anaphylaxis. The Konakion MM 10mg/mL should be used for intravenous administration. Administration should be:
- •By slow IV bolus (see IV Manual for directions for administration).
- •Withheld in patients with a history of previous severe allergic reaction to vitamin K
- ♦ Oral Vitamin K preparation used is Konakion MM Paediatric, which comes in a concentration of 2mg/0.2mL. The oral syringes provided with each pack to be used to measure the required volume to be given orally. These syringes explicitly state 1mg and 2mg on the markings.

Standard risk patients do not require INR reversal at INR 4.5 - 6.9 but correction should be considered in "high risk" patients whose risk of bleeding is approximately 15 fold higher.



## Patients at high risk of warfarin associated bleeding: Elderly

Previous GI bleed

Previous CVA (haemorrhagic or ischaemic)

Anaemia

Renal failure

Diabetes mellitus

Previous MI